Alpine Immune Sciences
Rupert Davies is an experienced professional in the field of translational medicine and biotechnology, currently serving as Executive Director of Translational Medicine at Alpine Immune Sciences, Inc. since May 2022. Prior to this role, Rupert held various positions at Zymeworks Inc. from January 2015 to April 2022, including Senior Director of Translational Sciences, Director of Pharmacokinetics, Principal Scientist in Oncology, and Senior Scientist in Preclinical Development. Rupert's experience also includes serving as Preclinical Manager at Amgen, Manager of Preclinical Development at Sarepta Therapeutics, and Manager of R&D at Implicit Bioscience. Rupert founded Allomodus, LLC, and has held a Senior Fellow position at the University of Washington. Rupert earned a PhD in Bioengineering from the University of Utah and a BSE in Civil and Environmental Engineering from the University of Michigan, with post-doctoral studies in Bioengineering from the University of Washington.
This person is not in any teams
This person is not in any offices
Alpine Immune Sciences
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), is a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- orbest-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients’ lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development.